{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T20:33:35Z","timestamp":1778186015196,"version":"3.51.4"},"reference-count":44,"publisher":"American Society of Hematology","issue":"20","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,10,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is a rare, life-threatening disorder of systemic microthrombosis and organ ischemia. The etiology of chronic cerebrovascular outcomes in iTTP survivors is largely unknown. In this pilot study, we measured blood\u2013brain barrier (BBB) permeability in patients with iTTP at the start of remission and 6 months later. This prospective pilot study included 7 adult patients with incident iTTP. Eligibility criteria included ADAMTS13 activity &amp;lt; 10% and detectable inhibitor at diagnosis. Patients were recruited from London Health Sciences Centre in Canada (2017-2019) within 3 days of hospital admission and followed for 6 months after remission (defined as normalization of platelet count and lactate dehydrogenase with no clinical signs or symptoms of microvascular injury for more than 30 days after the last plasma exchange). All patients had cerebral computed tomography perfusion scans with BBB permeability surface product measurements. Patients (5 women, 2 men) had a mean age of 48 years (range, 21-77 years). At diagnosis, patients had a mean platelet count of 22 (standard deviation [SD], 25) \u00d7 109\/L. At the start of remission, mean BBB permeability surface product was 0.91 (0.30) mL\/min\/100 g. Six months later, the mean permeability surface product was 0.56 (0.22) mL\/min\/100 g, with a mean difference of \u22120.312 mL\/min\/100 g (95% confidence interval: \u22120.4729 to \u22120.1510; P = .0032). In this pilot study of patients with iTTP, pathologically increased BBB permeability was evident, and although there was some improvement, this persisted 6 months after remission. Future work will explore the chronicity of these findings and their clinical implications.<\/jats:p>","DOI":"10.1182\/bloodadvances.2021005317","type":"journal-article","created":{"date-parts":[[2021,9,14]],"date-time":"2021-09-14T22:00:00Z","timestamp":1631656800000},"page":"4211-4218","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":12,"title":["Blood\u2013brain barrier permeability in survivors of immune-mediated thrombotic thrombocytopenic purpura: a pilot study"],"prefix":"10.1182","volume":"5","author":[{"given":"Shih-Han Susan","family":"Huang","sequence":"first","affiliation":[{"name":"Department of Medicine;"},{"name":"Lawson Health Research Institute, London, Canada;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katerina","family":"Pavenski","sequence":"additional","affiliation":[{"name":"Department of Hematology, St. Michael\u2019s Hospital, Toronto, Canada;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7605-9752","authenticated-orcid":false,"given":"Ting-Yim","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Medical Biophysics, Western University, London, Canada;"},{"name":"Lawson Health Research Institute, London, Canada;"},{"name":"Department of Medical Imaging, Western University, London, Canada;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael T.","family":"Jurkiewicz","sequence":"additional","affiliation":[{"name":"Department of Medical Imaging, Western University, London, Canada;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aditya","family":"Bharatha","sequence":"additional","affiliation":[{"name":"Department of Radiology, St. Michael\u2019s Hospital, Toronto, Canada;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6132-3020","authenticated-orcid":false,"given":"Jonathan Dale","family":"Thiessen","sequence":"additional","affiliation":[{"name":"Department of Medical Biophysics, Western University, London, Canada;"},{"name":"Lawson Health Research Institute, London, Canada;"},{"name":"Department of Medical Imaging, Western University, London, Canada;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keith","family":"St. Lawrence","sequence":"additional","affiliation":[{"name":"Department of Medical Biophysics, Western University, London, Canada;"},{"name":"Lawson Health Research Institute, London, Canada;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7578-4469","authenticated-orcid":false,"given":"Jean","family":"Th\u00e9berge","sequence":"additional","affiliation":[{"name":"Department of Medical Biophysics, Western University, London, Canada;"},{"name":"Lawson Health Research Institute, London, Canada;"},{"name":"Department of Medical Imaging, Western University, London, Canada;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Mandzia","sequence":"additional","affiliation":[{"name":"Department of Neurology, Western University, London, Canada;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Barth","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Medical Oncology and Hematology, University Health Network, Toronto, Canada; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Licht","sequence":"additional","affiliation":[{"name":"Department of Pediatric, Division of Nephrology, SickKids Hospital, Toronto, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2089-8650","authenticated-orcid":false,"given":"Christopher Jordan","family":"Patriquin","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Medical Oncology and Hematology, University Health Network, Toronto, Canada; and"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","published-online":{"date-parts":[[2021,10,22]]},"reference":[{"issue":"2","key":"2021102215241169900_B1","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1002\/ajh.2830500203","article-title":"Increasing mortality from thrombotic thrombocytopenic purpura in the United States: analysis of national mortality data, 1968-1991","volume":"50","author":"T\u00f6r\u00f6k","year":"1995","journal-title":"Am J Hematol."},{"issue":"1","key":"2021102215241169900_B2","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1111\/j.1365-2141.2008.07317.x","article-title":"Treating TTP\/HUS with plasma exchange: a single centre\u2019s 25-year experience","volume":"143","author":"Forzley","year":"2008","journal-title":"Br J Haematol."},{"issue":"112","key":"2021102215241169900_B3","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1038\/ki.2008.609","article-title":"The thrombotic thrombocytopenic purpura and hemolytic uremic syndromes: overview of pathogenesis (experience of the Oklahoma TTP-HUS Registry, 1989-2007)","volume":"75","author":"George","year":"2009","journal-title":"Kidney Int Suppl."},{"issue":"20","key":"2021102215241169900_B4","doi-asserted-by":"crossref","first-page":"4060","DOI":"10.1182\/blood-2010-07-271445","article-title":"How I treat patients with thrombotic thrombocytopenic purpura: 2010","volume":"116","author":"George","year":"2010","journal-title":"Blood."},{"issue":"3","key":"2021102215241169900_B5","doi-asserted-by":"crossref","first-page":"357","DOI":"10.7326\/0003-4819-91-3-357","article-title":"The heart and cardiac conduction system in thrombotic thrombocytopenic purpura. A clinicopathologic study of 17 autopsied patients","volume":"91","author":"Ridolfi","year":"1979","journal-title":"Ann Intern Med."},{"issue":"6","key":"2021102215241169900_B6","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJM199108083250604","article-title":"Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura","volume":"325","author":"Rock","year":"1991","journal-title":"N Engl J Med."},{"issue":"2","key":"2021102215241169900_B7","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/00005792-196603000-00003","article-title":"Thrombotic thrombocytopenic purpura: report of 16 cases and review of the literature","volume":"45","author":"Amorosi","year":"1966","journal-title":"Medicine (Baltimore)."},{"issue":"3","key":"2021102215241169900_B8","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/j.1365-2141.2012.09167.x","article-title":"Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies","volume":"158","author":"Scully","year":"2012","journal-title":"Br J Haematol."},{"issue":"5","key":"2021102215241169900_B9","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1111\/j.1365-2141.2005.05512.x","article-title":"The course of ADAMTS-13 activity and inhibitor titre in the treatment of thrombotic thrombocytopenic purpura with plasma exchange and vincristine","volume":"129","author":"B\u00f6hm","year":"2005","journal-title":"Br J Haematol."},{"issue":"5","key":"2021102215241169900_B10","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1111\/j.1365-2141.2005.05681.x","article-title":"Splenectomy for the treatment of thrombotic thrombocytopenic purpura","volume":"130","author":"Kappers-Klunne","year":"2005","journal-title":"Br J Haematol."},{"issue":"8","key":"2021102215241169900_B11","first-page":"844","article-title":"Frequently relapsing thrombotic thrombocytopenic purpura treated with cytotoxic immunosuppressive therapy","volume":"86","author":"Allan","year":"2001","journal-title":"Haematologica."},{"issue":"3","key":"2021102215241169900_B12","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1111\/j.1365-2141.2007.06819.x","article-title":"Cyclosporin and plasma exchange in thrombotic thrombocytopenic purpura: long-term follow-up with serial analysis of ADAMTS13 activity","volume":"139","author":"Cataland","year":"2007","journal-title":"Br J Haematol."},{"issue":"25","key":"2021102215241169900_B13","doi-asserted-by":"crossref","first-page":"3860","DOI":"10.1182\/blood-2014-11-551580","article-title":"How I treat refractory thrombotic thrombocytopenic purpura [correction published in Blood. 2017;130(14):1684]","volume":"125","author":"Sayani","year":"2015","journal-title":"Blood."},{"issue":"12","key":"2021102215241169900_B14","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1182\/blood-2013-04-496752","article-title":"Multiple major morbidities and increased mortality during long-term follow-up after recovery from thrombotic thrombocytopenic purpura","volume":"122","author":"Deford","year":"2013","journal-title":"Blood."},{"issue":"5","key":"2021102215241169900_B15","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1111\/trf.14060","article-title":"Depression and cognitive deficits as long-term consequences of thrombotic thrombocytopenic purpura","volume":"57","author":"Falter","year":"2017","journal-title":"Transfusion."},{"issue":"6","key":"2021102215241169900_B16","doi-asserted-by":"crossref","first-page":"3326","DOI":"10.1073\/pnas.1914655117","article-title":"Molecular adaptations of the blood\u2013brain barrier promote stress resilience vs. depression","volume":"117","author":"Dudek","year":"2020","journal-title":"Proc Natl Acad Sci U SA."},{"issue":"2","key":"2021102215241169900_B17","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41591-018-0297-y","article-title":"Blood-brain barrier breakdown is an early biomarker of human cognitive dysfunction","volume":"25","author":"Nation","year":"2019","journal-title":"Nat Med."},{"issue":"3","key":"2021102215241169900_B18","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1148\/radiol.2503080257","article-title":"Hemorrhagic transformation of ischemic stroke: prediction with CT perfusion","volume":"250","author":"Aviv","year":"2009","journal-title":"Radiology."},{"issue":"1","key":"2021102215241169900_B19","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s00330-011-2260-x","article-title":"Non-invasive assessment of functionally relevant coronary artery stenoses with quantitative CT perfusion: preliminary clinical experiences","volume":"22","author":"So","year":"2012","journal-title":"Eur Radiol."},{"issue":"5","key":"2021102215241169900_B20","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1007\/s10554-011-9927-x","article-title":"Quantitative myocardial perfusion measurement using CT perfusion: a validation study in a porcine model of reperfused acute myocardial infarction","volume":"28","author":"So","year":"2012","journal-title":"Int J Cardiovasc Imaging."},{"issue":"2","key":"2021102215241169900_B21","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1002\/(SICI)1096-8652(199702)54:2<102::AID-AJH2>3.0.CO;2-0","article-title":"Thrombotic thrombocytopenic purpura: early and late responders","volume":"54","author":"Sarode","year":"1997","journal-title":"Am J Hematol."},{"issue":"2","key":"2021102215241169900_B22","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/jth.13571","article-title":"Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies","volume":"15","author":"Scully","year":"2017","journal-title":"J Thromb Haemost."},{"issue":"1","key":"2021102215241169900_B23","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.acra.2012.08.013","article-title":"The effect of scan duration on the measurement of perfusion parameters in CT perfusion studies of brain tumors","volume":"20","author":"Yeung","year":"2013","journal-title":"Acad Radiol."},{"key":"2021102215241169900_B24","volume-title":"Computed Tomography\u2014Approaches, Applications, and Operations.","author":"Lee","year":"2020"},{"issue":"1","key":"2021102215241169900_B25","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1038\/s41598-017-01922-x","article-title":"Quantification of blood-brain barrier permeability by dynamic contrast-enhanced NIRS","volume":"7","author":"Milej","year":"2017","journal-title":"Sci Rep."},{"issue":"3","key":"2021102215241169900_B26","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S1052-3057(10)80171-5","article-title":"Thrombotic thrombocytopenic purpura: a neurological perspective","volume":"5","author":"Oberlander","year":"1995","journal-title":"J Stroke Cerebrovasc Dis."},{"issue":"5","key":"2021102215241169900_B27","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1111\/bjh.17126","article-title":"Cerebral MRI findings predict the risk of cognitive impairment in thrombotic thrombocytopenic purpura","volume":"191","author":"Alwan","year":"2020","journal-title":"Br J Haematol."},{"key":"2021102215241169900_B28","author":"Hamilton","year":"2021"},{"issue":"6","key":"2021102215241169900_B29","doi-asserted-by":"crossref","first-page":"e005819","DOI":"10.1161\/JAHA.117.005819","article-title":"Blood-brain barrier disruption, vascular impairment, and ischemia\/reperfusion damage in diabetic stroke","volume":"6","author":"Venkat","year":"2017","journal-title":"J Am Heart Assoc."},{"issue":"8","key":"2021102215241169900_B30","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.arcmed.2014.11.013","article-title":"Role of the blood-brain barrier in multiple sclerosis","volume":"45","author":"Ortiz","year":"2014","journal-title":"Arch Med Res."},{"issue":"6","key":"2021102215241169900_B31","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1191\/1352458503ms965oa","article-title":"Blood-brain barrier disruption in multiple sclerosis","volume":"9","author":"Minagar","year":"2003","journal-title":"Mult Scler."},{"issue":"1","key":"2021102215241169900_B32","first-page":"182","article-title":"Platelets contribute to BBB disruption induced by HIV and alcohol","volume":"3","author":"Nair","year":"2015","journal-title":"J Alcohol Drug Depend."},{"issue":"5","key":"2021102215241169900_B33","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s00259-003-1430-8","article-title":"Database of normal human cerebral blood flow, cerebral blood volume, cerebral oxygen extraction fraction and cerebral metabolic rate of oxygen measured by positron emission tomography with 15O-labelled carbon dioxide or water, carbon monoxide and oxygen: a multicentre study in Japan","volume":"31","author":"Ito","year":"2004","journal-title":"Eur J Nucl Med Mol Imaging."},{"issue":"3","key":"2021102215241169900_B34","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S1053-8119(03)00156-3","article-title":"Regional distribution of human cerebral vascular mean transit time measured by positron emission tomography","volume":"19","author":"Ito","year":"2003","journal-title":"Neuroimage."},{"issue":"16","key":"2021102215241169900_B35","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1182\/blood-2018-04-841247","article-title":"Silent infarcts in sickle cell disease occur in the border zone region and are associated with low cerebral blood flow","volume":"132","author":"Ford","year":"2018","journal-title":"Blood."},{"issue":"16","key":"2021102215241169900_B36","doi-asserted-by":"crossref","first-page":"4249","DOI":"10.1088\/0031-9155\/53\/16\/003","article-title":"Hepatic perfusion in a tumor model using DCE-CT: an accuracy and precision study","volume":"53","author":"Stewart","year":"2008","journal-title":"Phys Med Biol."},{"issue":"3","key":"2021102215241169900_B37","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1148\/radiol.11110331","article-title":"Reproducibility of CT perfusion parameters in liver tumors and normal liver","volume":"260","author":"Ng","year":"2011","journal-title":"Radiology."},{"issue":"3","key":"2021102215241169900_B38","first-page":"171","article-title":"CT imaging of angiogenesis","volume":"47","author":"Lee","year":"2003","journal-title":"Q J Nucl Med."},{"issue":"8","key":"2021102215241169900_B39","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1002\/ajh.24060","article-title":"Depression and cognitive impairment following recovery from thrombotic thrombocytopenic purpura","volume":"90","author":"Han","year":"2015","journal-title":"Am J Hematol."},{"issue":"13","key":"2021102215241169900_B40","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1182\/blood.2019001056","article-title":"Reduced ADAMTS13 activity during TTP remission is associated with stroke in TTP survivors","volume":"134","author":"Upreti","year":"2019","journal-title":"Blood."},{"issue":"7","key":"2021102215241169900_B41","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1161\/STROKEAHA.113.001558","article-title":"Effects of microvascular permeability changes on contrast-enhanced T1 and pharmacokinetic MR imagings after ischemia","volume":"44","author":"Liu","year":"2013","journal-title":"Stroke."},{"issue":"4","key":"2021102215241169900_B42","doi-asserted-by":"crossref","first-page":"779","DOI":"10.3324\/haematol.2013.094151","article-title":"Persistence of circulating ADAMTS13-specific immune complexes in patients with acquired thrombotic thrombocytopenic purpura","volume":"99","author":"Ferrari","year":"2014","journal-title":"Haematologica."},{"key":"2021102215241169900_B43","first-page":"69","article-title":"A blood\u2013brain barrier overview on structure, function, impairment, and biomarkers of integrity","volume":"17","author":"Kadry","year":"2020","journal-title":"BMC."},{"issue":"4","key":"2021102215241169900_B44","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa1806311","article-title":"Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura","volume":"380","author":"Scully","year":"2019","journal-title":"N Engl J Med."}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/5\/20\/4211\/1830021\/advancesadv2021005317.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/5\/20\/4211\/1830021\/advancesadv2021005317.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,22]],"date-time":"2021-10-22T15:26:11Z","timestamp":1634916371000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/5\/20\/4211\/476902\/Blood-brain-barrier-permeability-in-survivors-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,22]]},"references-count":44,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2021,10,26]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2021005317","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,22]]}}}